Magnesium Carbonate Is an Effective Phosphate Binder for Chronic Hemodialysis Patients: A Pilot Study

Journal of Renal Nutrition

Volumn 17, Issue 6, 2007, Pages 416-422

  Spiegel, David M ^a   Farmer, Beverly ^a   Smits, Gerard ^b   Chonchol, Michel ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b Computer and Statistical Consultants Inc ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAGNESIUM; MAGNESIUM CARBONATE; PHOSPHATE; PHOSPHORUS;

ARTICLE; BLOOD; CALCIUM INTAKE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISORDERS OF MINERAL, ELECTROLYTE AND METAL METABOLISM; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY; TREATMENT OUTCOME;

CALCIUM, DIETARY; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MAGNESIUM; MALE; MIDDLE AGED; PHOSPHATES; PHOSPHORUS; PHOSPHORUS METABOLISM DISORDERS; PROSPECTIVE STUDIES; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 35548990525     PISSN: 10512276     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jrn.2007.08.005     Document Type: Article

References (20)

1. Block G.A., Klassen P.S., Lazarus J.M., et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 14 (2004) 2208-2218
2. Young E.W., Albert J.M., Satayathum S., et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 67 (2005) 1179-1187
3. Kidney Disease Outcomes Quality Initiative (K/DOQI) Group. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42 Suppl (2003) S1-S201
4. Bushinsky D.A. Phosphate binders: hold the calcium?. Clin J Am Soc Nephrol 1 (2006) 695-696
5. Moe S.M., and Chertow G.M. The case against calcium-based phosphate binders. Clin J Am Soc Nephrol 1 (2006) 697-703
6. Friedman E.A. Calcium-based phosphate binders are appropriate in chronic renal failure. Clin J Am Soc Nephrol 1 (2006) 704-709
7. De Santo N.G., Frangiosa A., Anastasio P., et al. Sevelamer worsens metabolic acidosis in hemodialysis patients. J Nephrol 19 Suppl (2006) S108-S114
8. Finn W.F. Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients. Clin Nephrol 65 (2006) 191-202
9. Qunibi W.Y., Hootkins R.E., McDowell L.L., et al. Treatment of hyperphosphatemia in hemodialysis patients: the Calcium Acetate Renagel Evaluation (CARE) Study. Kidney Int 65 (2004) 1914-1926
10. Fine K.D., Santa Ana C.A., Porter J.L., and Fordtran J.S. Intestinal absorption of magnesium from food and supplements. J Clin Invest 88 (1991) 396-402
11. Guillot A.P., Hood V.L., Runge C.F., and Gennari F.J. The use of magnesium-containing phosphate binders in patients with end-stage renal disease on maintenance hemodialysis. Nephron 30 (1982) 114-117
12. Oe P.L., Lips P., van der Meulen J., et al. Long-term use of magnesium hydroxide as a phosphate binder in patients on hemodialysis therapy. Clin Nephrol 28 (1987) 180-185
13. O'Donovan R., Baldwin D., Hammer M., et al. Substitution of aluminum salts by magnesium salts in control of dialysis hyperphosphatemia. Lancet 1 (1986) 880-882
14. Parsons V., Baldwin D., Moniz C., et al. Successful control of hyperparathyroidism in patients on continuous ambulatory peritoneal dialysis using magnesium carbonate and calcium carbonate as phosphate binders. Nephron 63 (1993) 379-383
15. Delmez J.A., Kelber J., Norword K.Y., et al. Magnesium carbonate as a phosphate binder: a prospective controlled, crossover study. Kidney Int 49 (1996) 163-167
16. Cronin R.E. Magnesium disorders. In: Kokko J.P., and Tannen R.L. (Eds). Fluid and electrolytes (1986), W.B. Saunders Co., Philadelphia 502-512
17. Nilsson P., Johansson S.G., and Danielson B.G. Magnesium studies in hemodialysis patients before and after treatment with low dialysate magnesium. Nephron 37 (1984) 25-29
18. Gonella M., Ballanti P., Rocca C.D., et al. Improved bone morphology by normalizing serum magnesium in chronically hemodialyzed patients. Miner Electrolyte Metab 14 (1988) 240-245
19. Meema H.E., Oreopoulos D.G., and Rapoport A. Serum magnesium level and arterial calcification in end-stage renal disease. Kidney Int 32 (1987) 388-394
20. Tzanakis I., Pras A., Kounali D., et al. Mitral annular calcifications in haemodialysis patients: a possible protective role of magnesium. Nephrol Dial Transplant 12 (1997) 2036-2037